M&A: CITIUS ONCOLOGY, INC.

Form Type: 10-K

Filing Date: 2024-12-27

Corporate Action: Merger

Type: New

Accession Number: 000121390024113150

Comments: Citius Oncology, Inc. is a biopharmaceutical company focused on developing targeted oncology therapies, particularly LYMPHIR, which received FDA approval in August 2024 for treating patients with persistent or recurrent CTCL. The report highlights the company's business development, emphasizing its strategy to achieve a market-leading position by advancing innovative therapies. Notably, it discusses the merger with TenX Keane Acquisition that was completed on August 12, 2024, with Citius Pharma owning approximately 92.3% of the outstanding shares post-merger. The company also faces operational challenges, such as securing substantial funding, the commercialization of LYMPHIR, and navigating a competitive market landscape.

Document Link: View Document